Mood8 min
What the mood trials measured
People take saffron for a lighter mood. In mild to moderate depression, several reviews found better scores than placebo, and scores near the antidepressants used in those small trials. The papers are linked. None of them is a dose.
People take saffron because they want a lighter mood, less anxiety, or something to set beside a prescription. The largest set of trials is on mood, mostly in adults with mild to moderate depression, and several of those trials did find a change on the scales they used. What follows is a reading of those papers. It is not a dose, and it is not a diagnosis. Researchers compared a daily extract with placebo and, in some trials, with a common antidepressant. The courses people cite often ran about six weeks, and sometimes out to twelve. The tool was usually a symptom scale, such as the Hamilton Rating Scale for Depression or the Beck Depression Inventory.
What the reviews report
A 2020 systematic review and meta-analysis pooled twelve studies of mild to moderate depression. The authors reported better scores than placebo, and scores in the same range as the synthetic antidepressants used in the head-to-head trials. They found no clear difference in adverse effects against either comparison. Their own conclusion was that larger multicenter trials, run for longer and in more than one population, were still required. You can read that paper on PubMed, record 32221179. The authors wrote that saffron could be considered an alternative antidepressant. This desk will not hand you that sentence as a plan.
An earlier meta-analysis of seven trials, most of them using 30 milligrams a day for a mean of about seven weeks, reported more improvement than placebo. The authors called saffron effective, and comparable to the synthetic antidepressants in those trials. Their conclusion stays with them. The complaints recorded among people taking saffron in that analysis included appetite change, anxiety, headache, and nausea. The paper is open on PubMed Central, PMC5967372. A jar of threads is not the product they studied.
A 2025 meta-analysis compared saffron with SSRI antidepressants across eight depression trials and found no significant difference on the depression scores it pooled. Four anxiety trials in the same review also showed no clear difference. People on saffron had somewhat fewer recorded adverse events than people on the SSRIs. The authors still said that larger and more varied trials were needed. The record is PubMed 38913392.
What a later review could not make uniform
A 2026 review in Nutritional Neuroscience pooled 34 randomized trials and 1,769 adults. On the Beck Depression Inventory and the Beck Anxiety Inventory, the pooled scores moved. On the Hamilton depression and anxiety scales, and on one mood profile, the same review found no significant effect. The authors rated the certainty as moderate and the results as heterogeneous, which is a careful way of saying the trials do not all tell one story. The DOI is 10.1080/1028415X.2025.2602153. When two standard scales do not agree, the literature is still unsettled, and a cooking site has nothing further to declare.
Across these papers the trials are mostly small, and many of the early ones come from one or two countries. The products differ as well. A stigma extract, a petal extract, and a branded extract are not the same jar. A 2026 narrative review puts the common pattern at 30 milligrams a day for about six weeks, often as 15 milligrams twice a day, and it lists those limits plainly: PubMed 41939549. Some reviews propose serotonin, or other brain chemicals, as a reason the scores moved. A proposal in a discussion section is not a measurement this desk has made, and a thread does not become an antidepressant because a diagram mentions serotonin or dopamine.
How long did they watch? About six weeks in the trials people cite, and sometimes twelve. That length belongs to a study. It is not a promise that you will feel different on a given day, and it is not a course to begin. Short-term symptom scores leave every kind of depression, every age, and every other drug a person might already be taking still open. They also leave open the question of ordinary care, where a prescription is already in the house. The head-to-head trials were small and short, and this desk will not tell you to swap a prescription for a spice. Sleep scores and premenstrual scores come from different trials, written up apart from this page: sleep and the cycle. The unit those trials used, and why it is not a pinch, is on the pinch and the capsule.
A change on a symptom scale, in a small trial, is a finding. It is not a prescription, and it is not a jar of threads.
If you came to this page on a bad week and you are thinking about harming yourself, the next step is a person, not a spice. In the United States you can call or text 988, or visit 988lifeline.org. If you are elsewhere, use your local emergency number. Stopping a prescribed antidepressant is a decision for the clinician who started it. The situations that call for that conversation are on the caution page.
What the dried stigma looks like, before anyone crushes it, is on Saffron Threads. The gram, as a jar this suite could read, is on Saffron Price. The morning's labor, counted onto a plate, is on Saffron Cost. The older map, kept apart from a dose, is on Saffron History. If you are cooking, the bloom is on Saffron Cook, the rice is on Saffron Recipe, and the chicken, on another night, is on Saffron Chicken.
Also on this desk
- UnitsThe pinch and the capsule are not the same thing
- HarmSide effects, and the range that is no longer food
- CautionWhen a supplement is the wrong next step
- SleepWhat the sleep trials measured
- The cyclePremenstrual symptoms in a handful of trials
- EyesEyes, and a change smaller than one line
- The limitWhat the evidence does not support